title: Platelet-rich plasma and fibrin as delivery systems for recombinant human bone morphogenetic protein-2.
abstract: The aim of the present study was (1) to test whether or not platelet-rich plasma (PRP) or commercially available fibrin can increase bone regeneration compared with non-treated defects and (2) to test whether or not PRP or fibrin increases bone regeneration when used as a delivery system for recombinant human bone morphogenetic protein-2 (rhBMP-2). In 16 New Zealand White rabbits, four evenly distributed 6 mm diameter defects were drilled into the calvarial bone. The following five treatment modalities were randomly allocated to all 64 defects: (0) untreated control, (1) fibrin alone, (2) PRP alone, (3) fibrin with 15 microg rhBMP-2 and (4) PRP with 15 microg rhBMP-2. For the fibrin gels and the PRP containing rhBMP-2, the 15 microg rhBMP-2 was incorporated by precipitation within the matrices before their gelation. After 4 weeks, the animals were sacrificed and the calvarial bones were removed for histological preparation. The area fraction of newly formed bone was determined in vertical sections from the middle of the defect by applying histomorphometrical analysis. A mean area fraction of newly formed bone was found within the former defect of 23.4% (+/-13.5%) in the control sites, of 28.4% (+/-17.4%) in the fibrin sites and of 34.5% (+/-17.4%) in the PRP sites. The statistical analysis revealed no significant difference in bone formation between the three groups (ANOVA). Addition of 15 microg rhBMP-2 in the fibrin gel (59.9+/-20.3%) and the PRP gels (63.1+/-25.3%) increased bone formation significantly. No significant difference was observed between sites, where PRP or fibrin has been used as a delivery system for rhBMP-2 (ANOVA). In conclusion, the application of fibrin gels or PRP gels to bone defects is not superior to leaving the defect untreated. Regarding the amount of bone formation, the application of 15 microg rhBMP-2 in bone defects enhances the healing significantly at 4 weeks. In this animal model, commercially available fibrin and autologous PRP gels are equally effective as delivery systems for rhBMP-2.
authors.affiliation: Department of Fixed and Removable Prosthodontics and Dental Material Science, University of Zurich, Zurich, Switzerland. jung@zzmk.unizh.ch
authors.forename: Ronald E
authors.initials: RE
authors.lastname: Jung
authors.forename: Hugo G
authors.initials: HG
authors.lastname: Schmoekel
authors.forename: Roger
authors.initials: R
authors.lastname: Zwahlen
authors.forename: Vladimir
authors.initials: V
authors.lastname: Kokovic
authors.forename: Christoph H F
authors.initials: CH
authors.lastname: Hammerle
authors.forename: Franz E
authors.initials: FE
authors.lastname: Weber
mesh_terms: D000818:Animals; D001792:Blood Platelets; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins / Q000008:administration & dosage*; D001861:Bone Regeneration / Q000187:drug effects*; D016503:Drug Delivery Systems; D005337:Fibrin / Q000494:pharmacology*; D005782:Gels / Q000494:pharmacology; D006133:Growth Substances / Q000494:pharmacology; D006801:Humans; D023421:Models, Animal; D011817:Rabbits; D011897:Random Allocation; D011994:Recombinant Proteins / Q000008:administration & dosage; D016212:Transforming Growth Factor beta / Q000008:administration & dosage*
chemical_list: C525718:BMP2 protein, human; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins; D005782:Gels; D006133:Growth Substances; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta; D005337:Fibrin